The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CGEM | +82.94% | -71.72% | -22.32% | -50% |
| S&P | +20.78% | +72.15% | +11.48% | +77% |
Cullinan Oncology, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$79.00K | -2.6% |
| Market Cap | $611.44M | -13.8% |
| Market Cap / Employee | $5.61M | 0.0% |
| Employees | 109 | -1.8% |
| Net Income | -$50,713.00K | -6.4% |
| EBITDA | -$55,180.00K | -0.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $88.33M | 6.4% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.90M | 124.1% |
| Short Term Debt | $780.00K | -40.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -41.04% | -10.8% |
| Return On Invested Capital | -16.51% | -1.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$38,120.00K | -4.1% |
| Operating Free Cash Flow | -$38,109.00K | -4.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.75 | 0.80 | 0.71 | 1.35 | 20.10% |
| Price to Tangible Book Value | 0.75 | 0.80 | 0.71 | 1.35 | 20.10% |
| Enterprise Value to EBITDA | -2.62 | -2.38 | -0.34 | -4.30 | -25.28% |
| Return on Equity | -36.6% | -36.0% | -40.2% | -44.0% | 37.28% |
| Total Debt | $1.84M | $1.52M | $1.19M | $2.68M | 24.73% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
